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Deep brain stimulation (DBS) is a powerful neurostimulation therapy proposed for the treatment 
of several neuropsychiatric disorders. However, DBS mechanism of action remains unclear, being 
its effects on brain dynamics of particular interest. Specifically, DBS reversibility is a major point 
of debate. Preclinical studies in obesity showed that the stimulation of the lateral hypothalamus 
(LH) and nucleus accumbens (NAcc), brain centers involved in satiety and reward circuits, are able 
to modulate the activity of brain structures impaired in this pathology. Nevertheless, the long‑term 
persistence of this modulation after DBS withdrawal was unexplored. Here we examine the in vivo 
presence of such changes 1 month after LH‑ and NAcc‑DBS, along with differences in synaptic 
plasticity, following an exploratory approach. Thus, both stimulated and non‑stimulated animals 
with electrodes in the NAcc showed a common pattern of brain metabolism modulation, presumably 
derived from the electrodes’ presence. In contrast, animals stimulated in the LH showed a relative 
metabolic invariance, and a reduction of neuroplasticity molecules, evidencing long‑lasting neural 
changes. Our findings suggest that the reversibility or persistence of DBS modulation in the long‑term 
depends on the selected DBS target. Therefore, the DBS footprint would be influenced by the stability 
achieved in the neural network involved during the stimulation.
Deep brain stimulation (DBS) has elicited major interest in the fields of neurology and psychiatry since the 
mid-twentieth century as a promising alternative to the ablative neurosurgical  procedures1. From the early 50s 
to the late 70s, pioneer researchers such as Delgado, Bekthereva, Sem-Jacobsen and Cooper, first recognized the 
therapeutic potential of  DBS1–3. However, it was not until 1987 that Benabid and Pollack  discoveries4 established 
DBS as an effective treatment for movement disorders. This revolutionary success led to an increase of advocates 
for the implementation of DBS to treat psychiatric conditions, which contrasted with a general skepticism based 
on the controversial past of lesioning  psychosurgery1. Despite its polemic beginnings, DBS  benefits5–7 continue 
inspiring extensive research work in the psychiatric  field8. In this sense, besides its well-recognized role in treat-
ing motor  diseases9, DBS has already received FDA approval for obsessive–compulsive disorder (OCD) and 
focal epilepsy  treatment8.
Regardless of its undoubted efficacy, there are a wide number of unanswered questions concerning DBS 
mechanism of action and long-term impact. Several theories have arisen in the last decades, aiming to unify 
the brain effects induced by DBS  (see10 for a review). This lack of consensus responds to the dependency of 
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the observed effects on the brain target and disease under study. Furthermore, there are few studies describing 
the permanence of physiological effects after completing a DBS  protocol11–14. In this respect, the traditional 
conception attributes to DBS a reversible nature, describing a rebound of the symptoms after the stimulation 
 withdrawal15,16. However, some studies showed a lack of reinstatement of pathological symptoms following DBS 
removal (even after a long-term follow-up11,17), or a paradoxical improvement of the patient’s  symptomatology13. 
Consequently, there is still no obvious evidence of the underlying phenomena, while the study of the neural 
consequences during and after DBS treatment seems crucial to spread its application to other pathologies.
In this sense, treatment-resistant obesity appears as a candidate disease to benefit from this  therapy18. Obesity 
etiology involves a substantial neuropsychiatric component in which homeostatic and reward brain centers play 
crucial roles. Food intake activates the brain circuits related to reward, whose alteration leads to the adoption 
of compulsive behaviors, in much the same way as in drug  addiction19. Therefore, obesity can somewhat be 
considered a ‘food addiction’20,21.
Among the considered DBS targets against obesity, the hypothalamus emerges as a good candidate since it 
harbors the appetite (lateral hypothalamus, LH) and satiety brain cores (ventromedial hypothalamus, VMH)22. 
In fact, a pilot  study23 showed the safety of applying LH-DBS for treatment-resistant obesity and reported a 
significant reduction in body weight in two out of three patients studied. Further research showed that LH-DBS 
increased the resting metabolic rate of two patients with treatment refractory  obesity24, proposing a potential 
mechanism underlying the DBS efficacy. Furthermore, given that enhanced anticipation of the food rewarding 
properties may partially drive to its  consumption25, reward-related areas could also become successful targets 
for DBS. A major brain core belonging to this system is the nucleus accumbens (NAcc), whose stimulation could 
counteract the reward feeling associated with food intake and theoretically lead to weight  reduction22. Accord-
ingly, four clinical trials testing the efficacy of high frequency NAcc-DBS reported significant weight reductions 
in those patients who finished the follow-up  period26–29.
In previous studies, we showed that LH-DBS in a rat model of genetic obesity (Zucker rat) induced weight 
gain reductions and metabolic changes in brain regions related to the control of food  intake30. On the contrary, 
NAcc-DBS in the same model did not affect the weight gain, but led to metabolic changes in cognitive- and 
reward-related brain  regions31. In addition, despite the proven effects of DBS on neuronal  activity32,33, very 
few studies have explored its effects on synaptic structural plasticity, and they mainly focused on the quantifi-
cation of synapses via  synaptophysin34–36. Here, we have a two-fold aim: (1) to examine which brain changes 
remained 1 month after the end of LH- and NAcc-DBS by means of positron emission tomography (PET) with 
 [18F]-fluorodeoxyglucose studies, and (2) to evaluate the density of excitatory and inhibitory synaptic markers 
(VGAT and VGLUT1), together with an assessment of a plasticity related molecule PSA-NCAM (polysialylated 
form of the neural cell adhesion molecule), in two regions modulated by LH- and NAcc-DBS (i.e. the hippocam-
pus and entorhinal cortex) at this time point.
Methods
Our study resulted from a 1-month follow-up performed to the same animals included in previous works by 
our group, in which we addressed the effects of a 15-days intermittent protocol of high frequency DBS applied 
in  LH30 or  NAcc31 in a genetic animal model of obesity.
Animals. Adult male Zucker rats (fa/fa-, Charles Rivers Laboratories, Spain) (10-week old) (N = 25) were 
housed individually in a temperature- and humidity-controlled room on a 12  h dark/light cycle with food 
(standard laboratory chow) and water available ad libitum. Prior to the PET studies, animals were deprived of 
food but allowed free access to water for 6–8 h. Figure 1a summarizes the complete study design.
All experimental animal procedures were conducted according to European Communities Council Directive 
2010/63/EU and approved by the Ethics Committee for Animal Experimentation of Hospital Gregorio Marañón 
and Madrid Regional Government (PROEX 026/16).
Surgeries. Animals underwent stereotactic surgery when they reached 10  weeks of age under a mixture 
of ketamine/xylazine (100/10  mg/kg). Concentric bipolar platinum-iridium electrodes (Bilaney Consultants 
GmbH, Germany) were bilaterally implanted to target the NAcc (+ 1.2 mm posterior and + 1.5 mm lateral from 
bregma, − 8.2 mm ventral from the dura)37 (N = 15) and the LH (− 4.0 mm posterior and + 1.6 mm lateral from 
bregma, − 8.2 mm ventral from the dura)37 (N = 10). Acrylic dental cement (Technovit®, Heraeus-Kulzer, Ger-
many) was applied to fix the electrodes to the skull. A 3-days postoperative protocol was followed by providing 
ceftriaxone (100 mg/kg IM) and buprenorphine (0.1 mg/kg IP) doses to prevent infections and pain. The correct 
electrode location was verified by the acquisition of a computerized tomography (CT) image (Fig. 1b).
DBS protocol. The stimulation protocol started 7 days after surgery to ensure enough time for recovering. 
4 groups of animals were established: NAcc-sham (N = 9) and LH-sham (N = 4) (surgery but no stimulation), 
and NAcc-DBS (N = 6) and LH-DBS (N = 6) (surgery plus stimulation). An isolated stimulator device (CS 120 8i, 
CIBERTEC S.A., Spain) delivered the stimulation at a constant current of 150 µA (130 Hz) and a pulse width of 
100 µs. Stimulation was applied for 1 h/day over 15 days  (see30,31 for further details).
Imaging studies. Acquisition of static PET studies was performed 1 day and 1 month after the end of the 
DBS protocol, using a small-animal PET/CT scanner (ARGUS PET/CT, SEDECAL, Spain). 2-deoxy-2-[18F]
fluoro-D-glucose (FDG) (~ 37 MBq) was intravenously injected through the tail vein, allowing a total uptake 
period of 45 min. Each PET acquisition lasted 45 min. CT images were also obtained with the same scanner, 
and they were used to ensure the absence of electrode displacement along the study (Supplementary Figs. 1 and 
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2). Furthermore, an anatomical template for the voxelwise PET study was obtained by acquiring a T2 spin-echo 
magnetic resonance image (MRI) from a naïve animal with a 7-T Biospec 70/20 scanner (Bruker, Germany). 
Acquisition and reconstruction protocols have been thoroughly described  elsewhere30,31.
Immunofluorescence studies. At the end of post-1-month PET studies, all animals were perfused with a 
4% paraformaldehyde solution, and their brains were removed and stored under cryoprotection (30% sucrose in 
PBS 0.1, 48 h) until used. Brain tissue was cut in 50 µm-thick coronal sections using a freezing-sliding microtome 
(LEICA SM2010R, Leica, Germany) and collected in 10 subseries. Free-floating sections were used for immu-
nohistochemistry as previously  described38, using the following primary antibodies: polyclonal guinea pig anti-
vesicular glutamate transporter 1 (VGLUT1, 1:2000, Merck-Millipore, Spain), monoclonal rabbit anti-vesicular 
GABA transporter (VGAT, 1:1000, Synaptic Systems, Germany) and monoclonal IgM mouse anti-PSA-NCAM 
(PSA-NCAM, 1:700, Merck-Millipore, Spain).
Data processing and statistical analysis. PET data. PET data followed a preprocessing registration 
protocol previously  described31. We performed an iterative voxel value normalization  method39,40. This protocol 
provided a “non-significant area” (NSA), which served as a normalization region to standardize the intensity val-
ues in our PET studies (see Supplementary Fig. 3). Then, an analysis throughout the entire brain was performed 
to evaluate regional changes in brain glucose metabolism. Images were studied by voxel-wise analyses using 
SPM12 software (http://www.fil.ion.ucl.ac.uk/spm/softw are/spm12 /) with a multifactorial ANOVA (p < 0.01, 
uncorrected), considering group (sham, DBS) and time point (post-1-day, post-1-month) as study factors. In 
order to reduce type I error, only significant regions larger than 50 activated adjacent voxels were considered. A 
cluster-based multiple-comparison correction (p < 0.05) was applied to limit type II  errors41, but no further cor-
rections for multiple comparisons were applied related due to the exploratory nature of the study.
Immunofluorescence data. The images used for the analysis of neuropil puncta expressing VGAT, 
VGLUT1 and PSA-NCAM were obtained with a confocal microscope (Leica TCS SPE). We analyzed different 
layers of the hippocampal CA1 field (pyramidale, radiatum; − 3.6 mm posterior and 1.5–4 mm lateral from 
Bregma) and the lateral entorhinal cortex (layer I-II, layer III, deep layer (V and VI); − 5.2 mm posterior and 
6.7–8 mm lateral from Bregma). These regions were selected due to the effect of NAcc-DBS on hippocampal 
activity and neurogenesis  promotion42, the effect of LH-DBS on hippocampal brain  metabolism30, and its pro-
posed benefits on memory dependent on these brain  regions43.
Confocal z-stacks covering the whole depth of the sections were taken with 1 μm step size and only subsets of 
confocal planes with the optimal penetration level for each antibody were selected. On these planes, small regions 
of the neuropil (890 μm2) were selected for analysis, in order to avoid blood vessels and cell somata. Images were 
processed using FIJI/ImageJ  software44 as previously  described38. The number of the resulting dots per region was 
counted. Statistics were performed using the number of animals as the “n”. The data were subjected to Student’s 
T-test analysis and figures were plotted with GraphPad Prism 8.
Figure 1.  (a) Study design. Design of the experimental procedures performed during the study. (b) Electrodes 
placement verification. Sagittal and axial views of a CT scan of an animal registered to the MR template next to 
the correspondent slice  from38 to verify the correct electrode location in LH (left) and NAcc (right).
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Ethical approval. All applicable international, national, and/or institutional guidelines for the care and use 
of animals were followed.
Results
‘In vivo’ study of the DBS metabolic footprint. LH‑DBS produces long‑term regional changes after 
stimulation withdrawal. LH-sham and LH-DBS animals showed important differences in brain metabolism 
which persisted 1 month after DBS withdrawal (Table 1a,b) (Fig. 2). Thus, LH-sham group showed a bilateral 
reduction in brain metabolism in the caudate-putamen and somatosensory cortex, while increased FDG uptake 
was evident in different portions of the LH, amygdala, pituitary gland, ventral hippocampus and brainstem at 
post-1-month compared with post-1-day. On the contrary, LH-DBS animals showed very few changes, with in-
creased FDG uptake in the hippocampus, brainstem and cerebellum at post-1-month compared with post-1-day.
NAcc‑DBS effects barely persist over time. In contrast with LH-groups, NAcc-sham and NAcc-DBS animals did 
not differ as much when comparing brain metabolic changes 1 day and 1 month after the DBS protocol ending 
(Table 1c,d) (Fig. 3).
In NAcc-sham animals, a reduction in FDG uptake was detected in the orbital cortex, corpus callosum, 
inferior and superior colliculi, as well as increases in hypothalamus and brainstem 1 month after the first PET 
study. Similarly, NAcc-DBS animals showed a glucose metabolism decrease in somatosensory cortex, NAcc, 
corpus callosum, ectorhinal cortex, inferior and superior colliculi, together with an increase in hypothalamus 
and brainstem at post-1-month compared with post-1-day.
Density of PSA‑NCAM, VGLUT1 and VGAT expressing puncta in the neuropil of the hippocam‑
pus and the entorhinal cortex. DBS alters the density of PSA‑NCAM expressing puncta. Animals 
stimulated in LH showed a significant decrease in the density of puncta-expressing PSA-NCAM in the stra‑
tum pyramidale (p < 0.05) and a non-significant trend towards a decrease in the stratum radiatum compared to 
sham animals (Fig. 4). By contrast, we found a significant increase in the density of PSA-NCAM + puncta in the 
stratum radiatum (p < 0.05) and a non-significant trend towards an increase in the stratum pyramidale in NAcc-
DBS animals (Fig. 4). The density of puncta expressing PSA-NCAM in the entorhinal cortex was significantly 
decreased in the layer III (p < 0.001) of LH-DBS animals when compared with sham animals (Fig. 5), while no 
significant changes were observed between NAcc groups.
Table 1.  Permanence of brain metabolic changes 1 month after stimulation. AA amygdala, BS brainstem, 
Cb cerebellum, cc corpus callosum, CPu caudate-putamen, Ect ectorhinal cortex, Hi hippocampus, HTh 
hypothalamus, IC inferior colliculus, LH lateral hypothalamus, NAcc nucleus accumbens, OC orbital cortex, 
Pit pituitary gland S somatosensory cortex, SC superior colliculus, ROI region of interest. Side: Right (R) and 
Left (L). T t value, k cluster size. Glucose metabolism: Increase (↑) and Decrease (↓). pUNC p value uncorrected, 
FWE family wise error correction.
ROI Side T k ↓/↑ pUNC peak level pUNC cluster level pFWE cluster level
(A) LH-sham




 < 0.001  < 0.001Bs L-R 4.09  < 0.001






 < 0.001  < 0.001
2.59  < 0.001
Hi L 5.30 93 ↑  < 0.001 0.038 0.350
(C) NAcc-sham
SC-IC R 8.14 237 ↓  < 0.001 0.010 0.020
OC R 6.29 378 ↓  < 0,001 0.002 0.011
cc L 5.37 240 ↓  < 0.001 0.009 0.020
BS L-R 5.02 216 ↑  < 0.001 0.013 0.099
HTh L-R 4.68 291 ↑  < 0.001 0.005 0.039
(D) NAcc-DBS




 < 0.001  < 0.001
S-cc-NAcc L-R 5.92  < 0.001
HTh L-R 5.86 582 ↑  < 0.001  < 0.001 0.002
BS L-R 5.61 320 ↑  < 0.001 0.004 0.028
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DBS alters the density of VGAT and VGLUT1 expressing puncta in the entorhinal cortex, but not in the hippocam‑
pus. LH-DBS animals showed a significant decrease in the density of puncta expressing VGAT (p < 0.01) and a 
non-significant trend towards a decrease in those expressing VGLUT1 in the layers I/II and III of the entorhinal 
cortex. NAcc-DBS animals showed a significant decrease in the density of puncta expressing VGAT (p < 0.01) 
and VGLUT1 (p < 0.01) in the entorhinal cortex layers I/II (Fig. 5). No significant differences were found in the 
hippocampus (Fig. 4).
Discussion
To our knowledge, these results are the first to date on the use of small-animal FDG-PET and neuroplasticity 
markers to assess the persistence of DBS modulation 1 month after stimulation withdrawal. Thus, we provide 
evidence that (i) the magnitude of the long-term persistence of the DBS brain metabolic modulation depends 
on the brain target, (ii) the modulation induced by the electrode’s presence changes over time independently of 
the targeted brain structure, and (iii) DBS induce neuroplasticity changes that are evident even 1 month after 
the stimulation ending.
FDG-PET studies revealed that LH-sham, NAcc-sham and NAcc-DBS animals showed common patterns 
of metabolic modulation 1 month after the end of the DBS protocol, which contrast with the metabolic pattern 
observed in LH-DBS rats. In fact, a reduced metabolism in striatum and somatosensory cortex, along with an 
increase in brainstem and hypothalamus, are evident in the former three groups of animals. Not surprisingly, all 
these structures are strongly interconnected through hypothalamic projections and belong to the limbic  system45, 
suggesting that the lesion of a brain structure in a certain network evokes distant effects in functionally and 
physically connected regions. These similarities may respond to the long-term presence of the electrode and the 
Figure 2.  Persistence of DBS effects on brain metabolism 1 month after finishing LH-DBS treatment. Colored 
PET overlays on the MR reference represent the T-maps resulting from the post-1-month vs. post-1-day 
comparisons, indicating increased (hot colors) or decreased FDG uptake (cold colors), in LH-sham (left) and 
LH-DBS (right) animals, respectively. The color bars represent the T values scale corresponding to the PET 
overlays intensity. Hemispheres: Left (L), Right (R). AA amygdala, BS brainstem, Cb cerebellum, CPu caudate-
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derived  lesions6. The absence of therapeutic effect in NAcc-DBS animals, neither during the stimulation period 
nor after the 1-month  course31, as well as the fact that almost no metabolic change appeared in NAcc-DBS sub-
jects different from those present in NAcc-sham rats, could be the clues to understand this phenomenon. In this 
sense, the predominance of the electrode-derived effects over the stimulation ones might respond to the need for 
longer stimulation periods to influence the patients’  symptoms46, together with a lack of strength of the stimula-
tion impact inferred on brain networks. Together, both factors would lead to a weak cerebral modulation in the 
long-term, unable to produce the pursued clinical benefit. Thus, the microlesion impact on brain metabolism 
related to the DBS implants has been previously  demonstrated47–51. However, to our knowledge, this is the first 
study in reporting continuing physiological changes derived from the electrode’s presence alone (i.e. without 
any influence of stimulation) as far as 2 months after implantation. Therefore, our results provide a potential 
explanation to the sometimes great durability of clinical outcomes related to the electrode insertional  effect52, as 
this long-term metabolic modulation might be the reflect of underlying neuroplastic processes which, in some 
cases, may lead to important clinical benefits.
In contrast, LH-DBS rats exhibited an absence of almost any change in comparison with the previous PET ses-
sion, evidencing a greater permanence of the immediate DBS effects. This finding goes in line with other authors 
who suggest the existence of (almost) irreversible consequences of DBS after  treatment11,13,53. Furthermore, the 
sustained brain activation pattern over time could be related with the therapeutic effect, and hence the clinical 
benefit, observed in LH-DBS  animals17. In this sense, Ruge et al. reported that some dystonia patients who suc-
cessfully underwent DBS during several years showed a maintenance of the clinical benefits of the stimulation, 
even one year after turning off the  device11. However, they also found a great neurophysiological instability under 
that apparent clinical calm, hypothesizing that the stimulated system would be seeking for a balance which would 
Figure 3.  Persistence of DBS effects on brain metabolism 1 month after finishing NAcc-DBS treatment. 
Colored PET overlays on the MR reference represent the T-maps resulting from the post-1-month vs. post-1-
day comparisons, indicating increased (hot colors) or decreased FDG uptake (cold colors), in NAcc-sham (left) 
and NAcc-DBS (right) animals, respectively. The color bars represent the T values scale corresponding to the 
PET overlays intensity. Hemispheres: Left (L), Right (R). BS brainstem, cc corpus callosum, Ect ectorhinal cortex, 
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Figure 4.  DBS effects on synaptic plasticity in the hippocampus. (A) Panoramic view of the dorsal 
hippocampus immunostained for VGAT and VGLUT1. (B1) Panoramic view of CA1 region. (B2) Detailed 
view of the strata pyramidale and radiatum. (C,D) Expression of molecules related to neuronal plasticity in the 
stratum pyramidale of LH stimulated animals (C), and LH-sham animals (D). (E,F) Expression of molecules 
related to neuronal plasticity in the stratum pyramidale of NAcc stimulated animals (E) and in NAcc-sham 
animals (F). (G,H) Graphs showing the density of puncta (number of puncta/900 µm2) expressing PSA-NCAM, 
VGAT, VGLUT1 and the E/I balance in the rats receiving stimulation in the LH (G) and the NAcc (H). Student’s 
T-test, p-values: * < 0.05). VGAT vesicular GABA transporter; VGLUT vesicular glutamate transporter 1. Scale 
bar 500 µm for (A), 50 µm for (B1), 20 µm for (B2), 3 µm for (C–F).
Figure 5.  DBS effects on synaptic plasticity in the entorhinal cortex. (A) Panoramic view of the entorhinal 
cortex and ventral hippocampus immunostained for VGAT and VGLUT1. (B1) Panoramic view of the lateral 
entorhinal cortex. (B2) Detailed view of the layer III of the lateral entorhinal cortex. (C,D) Expression of 
molecules related to neuronal plasticity in layer III of LH stimulated animals (C) and in LH-sham animals (D). 
(E,F) Expression of molecules related to neuronal plasticity in layer III in NAcc-stimulated animals (E) and 
NAcc-sham animals (F). (G,H) Graphs showing the density of puncta (number of puncta/900 µm2) expressing 
PSA-NCAM, VGAT, VGLUT1 and the E/I balance in the rats receiving stimulation in the LH (G) and the 
NAcc (H). Student’s T-test, p-values: * < 0.05, ** < 0.01, *** < 0.001. VGAT vesicular GABA transporter; VGLUT 
vesicular glutamate transporter 1. Scale bar 500 µm for (A), 50 µm for (B1), 20 µm for (B2), 3 µm for (C–F).
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make the pathological symptoms evident when it was reached. Therefore, they reinforced the need to evaluate 
the long-term effects of a continuous DBS protocol.
Nevertheless, the ectorhinal cortex hypometabolism observed in NAcc-DBS rats suggests a certain reversibil-
ity and rebound effect of the stimulation-derived metabolic modulation, in agreement with previous  reports5,14,16. 
In fact, the absence of metabolic changes in NAcc-sham animals in this region, together with the opposite 
effects induced by the stimulation alone in the post-1-day  studies30,31, support this theory. Accordingly, Ewing 
and  Grace14 reinforced this idea with their finding of a reduction in local field potentials towards baseline levels 
only 48 h after completion of high-frequency stimulation in NAcc. From the clinical side, a one-week inactiva-
tion of the stimulation in OCD patients led to a relapse of the positive symptoms and a rebound of the negative 
 ones16, although this report did not specify the DBS targets stimulated or any physiological outcome under these 
symptomatologic features.
In addition to the regional differences in brain metabolism, DBS induced changes in neuronal plasticity 
patterns. The long-term effects of DBS on the expression of PSA-NCAM are indicative of ongoing changes in 
the circuitry. Particularly interesting are the changes observed in the hippocampus after NAcc stimulation, 
since both limbic regions are intensely  interconnected54,55. Closely related to our results, Schmuckermaier et al. 
found that intermittent NAcc-DBS (1 h/day) during only seven consecutive days promoted neuronal activity 
and neurogenesis in the hippocampus, as well as antidepressant effects (i.e. improvements in the performance 
of the forced swimming and tail suspension tests), in a murine model of enhanced anxiety and  depression56. In 
our study, the hippocampal increase in PSA-NCAM expression could be related both to changes in excitatory 
or inhibitory neurons, since in this limbic region, and especially in the strata of CA1 where measurements were 
performed, PSA-NCAM is expressed by both cell  types57. In fact, there is a tendency towards increased levels of 
VGAT and VGLUT1 in the hippocampus of NAcc-DBS group.
It is also interesting the lack of metabolic changes in LH-DBS animals, and the reduction in the density of 
PSA-NCAM expressing puncta both in hippocampus and entorhinal cortex layer III. This could explain the low 
levels of VGAT obtained because PSA-NCAM is a potent regulator of inhibitory cortical  networks58. Additionally, 
the most rostral region of the entorhinal cortex, as the piriform cortex layer II, harbors immature PSA-NCAM 
expressing neurons that progressively mature into excitatory neurons during adult  life59, and the decrease in the 
expression of this molecule may boost their differentiation.
Thus, DBS could produce changes in brain regions which would trigger prolonged neuroplasticity processes 
in structures related to the DBS target. In this sense, although  acute60 or early evaluations of DBS effects show 
more remarkable changes in brain glucose metabolism, the stimulation might drive long-lasting mechanisms of 
neuronal modulation which were not correlated with the metabolic state of these structures after a period without 
DBS. These findings match previously published effects of DBS on brain metabolism, showing that these effects 
seem to be transient in  nature61 and may not be captured by FDG-PET performed 1 month after stimulation 
removal. Future studies should evaluate whether these changes in the expression of molecules related to neuro-
transmission and neural plasticity occur in other brain areas, at different times from the stimulation ending, or 
whether they were attenuated immediately after stimulation.
Altogether, our results support the evidence that the physiological and clinical outcomes after DBS, not only 
in short- but in long-terms, are strongly dependent on the brain target selected for stimulation, even under 
identical stimulation protocols and pathological  conditions60. Therefore, under fixed stimulation conditions, 
DBS elicits the simultaneous activation of several molecular mechanisms, both at local and distant levels, which 
might interact but could not be gathered under a simple theoretical  explanation10. In this sense, the length of 
the modulation induced by the impact of the electrical stimulation in a certain brain target would determine the 
persistence of the derived clinical benefits. Thus, there is a need for deeper research exploring the chronic effects 
of DBS, not only during the stimulation, but also after withdrawal, in order to address the complex molecular 
mechanisms underlying these effects.
Nonetheless, our study has certain limitations. First, our sample sizes are small, although the number of ani-
mals in each group proved to be sufficiently large to detect statistically significant changes in glucose metabolism 
and neuroplasticity markers. Second, our results are based on the obese Zucker rats, meaning that the currently 
reported results could not extrapolate to other pathological conditions. Third, our imaging data were not sub-
jected to Bonferroni correction due to two main reasons: i) Such a strict policy as Bonferroni correction would 
have led to a much higher sample size, that on the other hand compromises the 3-R’s principle in animal experi-
ments; and ii) in the case of voxel-based brain-imaging analyses, Bonferroni correction is overconservative due 
to assuming independence of the voxels, which is not true due to the intrinsic spatial correlation of the voxels. 
However, the multiple-comparison strategy followed prevents an underestimation of real effects, and hence a 
reduction in  power41,62. Fourth, electrode placement for both targets may cross the lateral ventricle. On the one 
hand, the transventricular trajectory of the electrodes is avoided in clinical practice, as it has been related to a 
displacement of the electrodes. However, the stability of the electrode position throughout our study was con-
firmed with the three CT studies (immediately after the stereotactic surgery and before each PET study). On the 
other hand, transventricular trajectories have also been associated with serious neurological complications such 
as intraventricular hemorrhage, severe headache, postoperative confusion or  seizures63. In this regard, none of 
these effects were detected in the animals included in this study. Finally, our results using an intermittent DBS 
protocol may differ from the possible effects of a continuous stimulation, which may lead to deeper and steadier 
modulatory effects than those reported here. These points highlight the need for further studies with different 
experimental designs in order to provide more standardized results.
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Conclusion
In conclusion, this study allowed to address the long-term persistence of DBS effects, applied in two brain struc-
tures proposed as potential targets for the treatment of obesity, 1 month after stimulation withdrawal. NAcc-
DBS results supported the well-known reversibility related to DBS, only obtaining changes in those structures 
modulated by the DBS implants. Nevertheless, LH-DBS barely modifies the effects previously inferred to brain 
metabolism, and supports the relation between the preservation of the stimulation effects and the clinical benefit. 
Besides, the reduced expression of molecules related to neuronal plasticity in structures previously modulated 
by LH-DBS would support this reluctance to change. These contradictory results might possibly explain the dif-
ferences in the weight gain related outcomes under both DBS protocols. Therefore, the existence of long-term 
effects of DBS in the brain could be understood as the result of a functional stability achieved during stimulation, 
which would underlie a prolonged positive outcome for the subject.
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